drugset / Trial / NCT06825793
Semaglutide's Weight Loss Effects in Obesity
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |